Available datapackage for study 'A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS'

B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with
a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy
and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily,
will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients
will have an option to enter a long-term extension study after completing 12 weeks of
treatment.